Medication patterns in patients with autism: Temporal, regional, and demographic influences

Journal of Child and Adolescent Psychopharmacology

Volumn 15, Issue 1, 2005, Pages 116-126

  Aman, Michael G ^a   Lam, Kristen S L ^a   Van Bourgondien, Mary E ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CHLORAL HYDRATE; CHLORPROMAZINE; CLOMIPRAMINE; CLONIDINE; DEXAMPHETAMINE; FLUOXETINE; GUANFACINE; HALOPERIDOL; HYDROXYZINE; IMIPRAMINE; LORAZEPAM; MELATONIN; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PEMOLINE; PROPRANOLOL; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; SERTRALINE; THIORIDAZINE; UNINDEXED DRUG;

ADOLESCENT; ADULT; AGE; AGED; AUTISM; COMPARATIVE STUDY; DEMOGRAPHY; DISABILITY; DRUG USE; DRUG UTILIZATION; FAMILY; FEMALE; HEALTH CARE PLANNING; HUMAN; LONGITUDINAL STUDY; MALE; PRESCHOOL CHILD; REVIEW; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; DATA COLLECTION; DEMOGRAPHY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; NORTH CAROLINA; OHIO; PSYCHOTROPIC DRUGS; TIME FACTORS;

EID: 14944346244     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2005.15.116     Document Type: Review

References (29)

1. Aman MG: Stimulant drug effects in developmental disorders and hyperactivity: Toward a resolution of disparate findings. J Autism Dev Disord 12:385-398, 1982.
2. Aman MG: Stimulant drugs in the developmental disabilities revisited. J Dev Phys Disab 8:347-365, 1996.
3. Aman MG, Arnold LE, Armstrong SC: Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Ment Retard Dev Disab Res Rev 5:279-289, 1999.
4. Aman MG, Lam KL, Collier-Crespin A: Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord 33:527-534, 2003.
5. Aman MG, Langworthy KS: Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord 30:451-459, 2000.
6. Aman MG, Madrid A: Atypical antipsychotics in persons with developmental disabilities. Ment Retard Dev Disab Res Rev 5:253-263, 1999.
7. Aman MG, Sarphare G, Burrow W: Psychoactive drugs in group homes: Prevalence and relation to demographic/psychiatric variables. Am J Ment Retard 99:500-509, 1995a.
8. Aman MG, Van Bourgondien ME, Wolford PC, Sarphare G: Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 34:1672-1681, 1995b.
9. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
10. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19: 227-239, 1989.
11. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH: Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 141:1195-1202, 1984.
12. Davanzo P, McCracken J: Mood stabilizers: Lithium and anticonvulsants. In: Pediatric Psychopharmacology: Principles and Practice. Edited by Martin A, Scahill L, Charney DS, Lecktnan JF. New York: Oxford University Press, 2003, pp. 309-327.
13. Dewa CS, Goering P: Lessons learned from trends in psychotropic drug expenditures in a Canadian province. Psychiatr Serv 52:1245-1247, 2001.
14. Dewa CS, Remington G, Herrmann N, Fearnley J, Goering P: How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther 24:1466-1476, 2002.
15. Gordon C, State R, Nelson J, Hamburger S, Rapoport J: A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50:441-147, 1993.
16. Langworthy-Lam KL, Aman MG, Van Bourgondien ME: Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol 12:311-321, 2002.
17. Lord C, Rutter M, LeCouteur A: Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with pervasive developmental disorders. J Autism Dev Disord 24:659-685, 1994.
18. Martin A, Scahill L, Klin A, Volkmar F: Higher functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 38:923-931, 1999.
19. McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, Bell-Bradshaw F, Freeman BJ, Gates-Ulanet P, Martin A, McGough JJ, Posey DJ, Ritz L, Swiezy NB, Vitiello B, Volkmar FR, Walson P: Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Background and rationale for an initial controlled study of risperidone. In: Child and Adolescent Psychiatric Clinics of North America. Edited by Martin A, Scahill L. Philadelphia (Pennsylvania): WB Saunders Co., 2000, vol. 9, pp. 201-224.
20. Newcorn JH, Schultz KP, Halpern JM: Adrenergic agonists: Clonidine and guanfacine. In: Pediatric Psychopharmacology: Principles and Practice. Edited by Martin A, Scahill L, Charney DS, Leekman JF. New York: Oxford University Press, 2003, pp. 264-273.
21. Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML: Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996-2000. J Child Adolesc Psychopharmacol 12:221-229, 2002.
22. Research Units on Pediatric Psychopharmacology Autism Network: A double-blind, placebo-controlled trial of risperidone in children with autistic disorder. NEJM 347:314-321, 2002.
23. Rimland B: Controversies in the treatment of autistic children: Vitamin and drug therapy. J Child Neurol 3:S68-S72, 1988.
24. Rinck C: Epidemiology and psychoactive medication. In: Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Edited by Reiss S, Aman MG. Columbus (Ohio): Ohio State University Nisonger Center, 1998, pp. 31-44.
25. Singh NN, Ellis CR, Mulick JA, Poling A: Vitamin, mineral, and dietary treatments. In: Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Edited by Reiss S, Aman MG. Columbus (Ohio): Ohio State University Nisonger Center, 1998a, pp. 311-320.
26. Singh, NN, Ellis CR, Wechsler HA: Psychopharmacoepidemiology in mental retardation. J Child Adolesc Psychopharmacol 7:255-266, 1998b.
27. Stark JA, Menolascino FJ, Albarrelli MH, Gray VC (eds.): Mental Retardation and Mental Health: Classification, Diagnosis, Treatment, Services. New York: Springer-Verlag, 1987.
28. Walkup JT: Increasing use of psychotropic medications in children and adolescents: What does it mean? J Child Adolesc Psychopharmacol 13:1-3, 2003.
29. Zito SM, Safer DJ, dosReis S, Gardner JF, Magder L, Soeken K, Boles M, Lynch F, Riddle MA: Psychotropic practice patterns for youth. A 10-year perspective. Arch Ped Adolesc Med 157:17-25, 2003.